Loading clinical trials...
Loading clinical trials...
Early Clinical Study of Allogenic NK Cells (JD002) in Combination With Chemotherapy in the Treatment of Relapsed or Refractory(r/r) Acute Myeloid Leukemia(AML) After Allo-HSCT
Conditions
Interventions
allogenic NK cells
Locations
1
China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Start Date
March 1, 2023
Primary Completion Date
May 1, 2025
Completion Date
May 1, 2025
Last Updated
February 27, 2023
NCT06285890
NCT06220162
NCT04065399
NCT06484062
NCT06994676
NCT04628026
Junnian Zheng, M.D., Ph.D
CONTACT
Lead Sponsor
Xuzhou Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions